Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?

Sanchez-Salinas, Mario Andrés; Troconiz, Iñaki; Varela González-Aller, Javier; Miarons, Marta; Barba, Pere; IACOBONI, GLORIA; Navarro Garces, Victor

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Sanchez-Salinas, Mario Andrés
dc.contributor.author	Troconiz, Iñaki
dc.contributor.author	Varela González-Aller, Javier
dc.contributor.author	Miarons, Marta
dc.contributor.author	Barba, Pere
dc.contributor.author	IACOBONI, GLORIA
dc.contributor.author	Navarro Garces, Victor
dc.date.accessioned	2024-05-16T11:32:58Z
dc.date.available	2024-05-16T11:32:58Z
dc.date.issued	2024-05-14
dc.identifier.citation	Sánchez-Salinas MA, Miarons M, Troconiz IF, Navarro V, Varela J, Iacoboni G, et al. Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy? Blood Adv. 2024 May 14;8(9):2130–2.
dc.identifier.issn	2473-9537
dc.identifier.uri	https://hdl.handle.net/11351/11467
dc.description	Fludarabina; Células CAR-T
dc.language.iso	eng
dc.publisher	American Society of Hematology
dc.relation.ispartofseries	Blood Advances;8(9)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Cèl·lules B - Tumors
dc.subject	Limfomes - Quimioteràpia
dc.subject	Cèl·lules T - Ús terapèutic
dc.subject.mesh	Lymphoma, Large B-Cell, Diffuse
dc.subject.mesh	/drug therapy
dc.subject.mesh	Immunotherapy, Adoptive
dc.subject.mesh	Receptors, Chimeric Antigen
dc.title	Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1182/bloodadvances.2023011433
dc.subject.decs	linfoma de células B grandes difuso
dc.subject.decs	/farmacoterapia
dc.subject.decs	inmunoterapia adoptiva
dc.subject.decs	receptores de antígenos quiméricos
dc.relation.publishversion	https://doi.org/10.1182/bloodadvances.2023011433
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Sanchez-Salinas MA, Iacoboni G, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Miarons M] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Pharmacy Department, Consorci Hospitalari de Vic, Barcelona, Spain. [Troconiz IF] Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain. [Navarro V] Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Varela J] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid	38231085
dc.rights.accessrights	info:eu-repo/semantics/openAccess